Table 3.
Compiled Data on Functional Evaluation Outcomes. Due to Study Heterogeneity, Studies Were Divided Into the Functional Evaluation Metric They Utilized During the Study.
| Study | Data |
|---|---|
| Basso-Beattie-Bresnahan (BBB) | |
| Pedram et al38 | Meloxicam: 8, control: 0 (P < .05) |
| Campolo et al40,a | Control: 2, nap: 4, ATB-346: 7. Naproxen and ATB-346 (P < .05 when nap compared to control and ATB-346 compared to nap). |
| Wang et al36,a | Ibu: 9.4, control: 6.8, nap: 7.7. Ibuprofen (P < .01) compared to naproxen and control. |
| Sharp et al35,a | Control: 11.9 versus ibu: 11.2 (P > .05) |
| Redondo-Castro and Navarro39,a | Ibu: 16 versus control: 17 (P > .05) |
| Fu et al31,a | BBB evaluated 42 days after injury. In hemisection injury group = ibu: 15, nap: 13, control: 13. In contusion model the control was 13.5, ibu: 16 (P < .05 for both BBB injury mechanisms). |
| Hains et al33 | BBB evaluated 2 days after injury = NS-398: 0.9 ± 0.7, control: 1.1 ± 0.4. 14 days after injury = NS-398: 12.6 ± 0.77, control 10.2 ± 0.69 (P > .05). Day 28 NS-398: 17.4 ± 1.25, control: 14.6 ± 0.72 (P < .05). |
| Gale | |
| Hakan et al30,a | Noninjured group: 6. SCI group: 2.5, SCI + mel: 3.0 (P > .05) |
| Tarlov | |
| Pantović et al41 | Control: 1.3, 0.1 mg/kg ind: 2.2 mg/kg, 0.3 mg/kg ind: 2.2, ind 1.0 mg/kg: 2.3, ind 3.0 mg/kg: 2.7. P < .05 for all treated groups in dose dependent manner. |
| Filament test/grid walk failure rate/stride length | |
| Sharp et al35,a | Von Frey filament sensory testing showed no significant difference 9.2 g ±5.4 in saline treated rats versus 8.5 ± 5.7 in IBU treated. Hindlimb walk and grid walk test resulted in failure of 26.75% for the saline group versus 25.57% for the ibuprofen-treated group. Mean stride length was 158.5 mm for saline treated group and 153.4 mm for the ibuprofen treated group; mean stride width was approximately 28 mm for both treatment groups (P > .05). |
| Fu et al31,a | Grid walk failure rate in the hemisection injured group for control: 62%, naproxen: 62%, ibu: 50% (P < .05). Contusion model failure rate = control: 65% and ibu: 45% (P < .05). Stride length in hemisection group: control: 125 mm, nap: 130 mm, ibu: 145 mm (P < .05), stride width = control: 60 mm, nap: 50 mm, ibu: 40 mm (P < .05). |
| Coordination test/max speed | |
| Redondo-Castro and Navarro39,a | Fine motor coordination foot beam test for ibu group: 1.75 steps versus saline: 1.25 steps. Maximum speed on treadmill for control group: 37 versus ibu group: 34 (P > .05 for both tests). |
| Locomotor score | |
| Simpson et al34 | Locomotor score based on ability to ascend inclined plane. Noninjured group at day 1 and at 6 weeks: 69.9 ± 3.2 and 67.4 ± 2.8, SCI-vehicle group: 41.8 ± 12 and 56.9 ± 13.2, sham-ind group: 58.4 ± 5.2 and 64.9 ± 5.2, SCI-ind group: 37.4 and 67.4 ± 4.4 locomotor score for SCI-ind compared to SCI-vehicle (P < .05). Motor score based on 4-point scale from normal to no movement at day 1 and 6 weeks after injury. Noninjured group: 4.0 and 4.0, SCI-vehicle group: 2.7 ± 1.1 and 3.3 ± 1.2, sham-ind group: 4.0 and 4.0, SCI-ind group: 3.1 ± 0.6 and 4.0 ± 4.0, SCI-vehicle group: 1.2 ± 0.5 and 1.0 ± 0.0, sham-ind group: 1.9 ± 0.3 and 1.0 ± 0.0, SCI-ind group: 2.8 ± 0.6 and 1.0 ± 0.0 (P < .05 for ind vs control). |
Abbreviations: SCI, spinal cord injury; ind, indomethacin; ibu, ibuprofen; nap, naproxen; mel, meloxicam.
a Data estimated from figures in the original article.